Aim: The study was designed to evaluate the prognostic value of the 6-min walk test (6MWT) in patients with mild to moderate congestive heart failure (CHF). Methods and results: Two hundred and fourteen patients (119 men and 95 women, mean age 64 years) were followed for a mean period of 34 months to assess event-free survival (death, heart transplantation). Sixty-six patients (34%) died (63 cardiovascular causes, 2 cancer and 1 stroke) and five patients underwent heart transplantation. For patients who walked -300 m during the 6MWT, survival was 62% compared with 82% in patients who walked 300-450 m or)450 m. With univariate analysis, NYHA class was the strongest predictor of death. LVEF (P-0.0001), aetiology of heart failure (P-0.001), LV filling pattern (Ps0.002) and 6MWT distance (P-0.01) were all significantly related to survival. No significant relationship was found between survival, peak oxygen consumption or anaerobic threshold. Multivariate analysis using the Cox-stepwise regression model showed that LV fractional shortening (P-0.009) and 6MWT distance (P-0.0005) were the strongest prognostic markers. Conclusion: A 6MWT distance of -300 m is a simple and useful prognostic marker of subsequent cardiac death in unselected patients with mild to moderate CHF.
Acquired metallo--lactamases (MBLs) are resistance determinants of increasing clinical importance in Gram-negative bacterial pathogens, which confer a broad-spectrum -lactam resistance, including carbapenems. Several such enzymes have been described since the 1990s. In the present study, a novel acquired MBL, named FIM-1, was identified and characterized. The bla FIM-1 gene was cloned from a multidrug-resistant Pseudomonas aeruginosa clinical isolate (FI-14/157) cultured from a patient with a vascular graft infection in Florence, Italy. The isolate belonged in the sequence type 235 epidemic clonal lineage. The FIM-1 enzyme is a member of subclass B1 and, among acquired MBLs, exhibited the highest similarity (ca. 40% amino acid identity) with NDM-type enzymes. In P. aeruginosa FI-14/157, the bla FIM-1 gene was apparently inserted into the chromosome and associated with ISCR19-like elements that were likely involved in the capture and mobilization of this MBL gene. Transfer experiments of the bla FIM-1 gene to an Escherichia coli strain or another P. aeruginosa strain by conjugation or electrotransformation were not successful. The FIM-1 protein was produced in E. coli and purified by two chromatography steps. Analysis of the kinetic parameters, carried out with the purified enzyme, revealed that FIM-1 has a broad substrate specificity, with a preference for penicillins (except the 6␣-methoxy derivative temocillin) and carbapenems. Aztreonam was not hydrolyzed. Detection of this novel type of acquired MBL in a P. aeruginosa clinical isolate underscores the increasing diversity of such enzymes that can be encountered in the clinical setting.A cquired metallo--lactamases (MBLs) are resistance determinants of increasing clinical importance in Gram-negative bacterial pathogens, including Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative nonfermenters. These enzymes can degrade most -lactams, including carbapenems, and escape inhibition by the conventional -lactamase inhibitors or avibactam. Thus, they are able to confer an extended -lactam resistance profile to the bacterial host that is not reversible by -lactamase inhibitors (1).Acquired MBLs were detected since the early 1990s, the first representatives being IMP-and VIM-type enzymes (2-4). Thereafter, a number of additional lineages of acquired MBLs have been described, including the SPM-, GIM-, SIM-, KHM-, NDM-, AIM-, DIM-, SMB-, and TMB-type enzymes (5, 6; see also reference 1 and references therein). By convention, different MBL types diverge from each other at by least 30% at the amino acid sequence level (7). Enzymes of different types may differ in functional properties, and the corresponding genes may be associated with different types of mobile genetic elements responsible for their dissemination, such as mobile gene cassettes inserted into integrons, ISCR elements, or composite transposons (8, 9).We report here on the identification and characterization of a new type of acquired MBL, named FIM-1, in a multidrug-resistant clinical ...
Background: Stratification of the severity of heart failure has major prognostic and therapeutic implications. Aims: To Ž . prospectively compare different methods of assessment of functional capacity in patients with chronic heart failure CHF . Ž . Ž . Methods and results:We studied 143 patients 78 male and 65 female with CHF aged less than 70 years mean 57.3 years . Functional assessment was made clinically according to NYHA classification and according to the Goldman Activity Scale Ž . Ž . Classification GASC . Cardiovascular performance was measured by peak O consumption pVO and anaerobic threshold 2 2 Ž . Ž . AT at cardiopulmonary exercise test and by the distance walked during a 6-min walk test 6-MWT . Clinical scales resulted Ž significantly related. Peak VO and AT showed a mild relation with distance covered at 6-MWT r s 0.56 and r s 0.46, 2 . respectively . Concordance between NYHA classification and levels of performance at cardiopulmonary exercise test or at 6-MWT was less than 50%. Conclusion: Our results suggest that none of the usually employed methods give a definitive assessment of functional capacity of cardiovascular system and a high degree of discordance exists among the results of different tests in the same patient. Although NYHA classification maintains its value in clinical evaluation of patients with Ž . CHF, the 6-min walk test is recommended in patients with mild-to-moderate CHF II᎐III NYHA classes as a simple and useful screening test to select patients for further diagnostic evaluation. ᮊ
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.